Paper - WANFANG MED ONLINE

You Position: Home > Paper

Progress in prevention and treatment of HBV reactivation associated with chemotherapy in malignant tumor patients

( views:15, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 7

DOI:: 10.11569/wcjd.v24.i7.1048

Key Word:: 化学药物治疗;乙型肝炎病毒;再激活;预防;治疗;Chemotherapy;Hepatitis B virus;Reactivation;Prevention;Treatment

Abstract： It is believed that malignant tumor patients with hepatitis B virus (HBV) infection show a higher incidence of reactivation of HBV after receiving chemotherapy, which is fatal,suggesting that awareness of HBV reactivation and the principles of prevention and treatment is important.There are many studies on HBV reactivation, however, the data are scattered.Here, we summarize the current understanding of the prevention and treatment of HBV reactivation in malignant tumor patients with HBV after receiving chemotherapy, aiming at providing routine screening and treatment for these patients which protect them against reactivation of HBV and improve the quality of life of patients.

Reference

[1]贾继东.免疫抑制治疗与乙型肝炎病毒再激活[J].2006,(6).
[2]符颖,蒋炜.化疗相关HBV再激活及其对策[J].2009,(6).
[3]陈彦帆.化疗致乙肝病毒再激活研究进展[J].2011,(4).
[4]中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南（2015年版）[J].2015,(3).
[5]潘儒艳,蒋旭超,张华,等.非霍奇金淋巴瘤患者乙型肝炎病毒感染状况分析[J].2013,(4).
[6]印健,高苏俊,朱海杭.消化道恶性肿瘤化疗与乙型肝炎病毒再激活的临床分析[J].2013,(11).
[7]姜枫,杨大明,徐克成.乙型肝炎病毒相关性肝细胞癌抗病毒治疗的研究进展[J].2015,(1).
[8]罗生强,张玲霞.2007年美国慢性乙型肝炎诊治推荐意见简介[J].2007,(6).
[9]李新慧,吴超.乙肝病毒再激活的危险因素和防治方案[J].2011,(1).
[10]饶洁,于世英.癌症患者HBV再激活发生的现况、机制和防治策略[J].2014,(4).
[11]中华医学会血液学分会,中国抗癌协会淋巴瘤专业委员会,中华医学会肝病学分会.中国淋巴瘤合并HBV感染患者管理专家共识[J].2013,(11).
[12][Noauthornameavailable].EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J].2012,57(1).
[13]范玲燕,周智.免疫抑制状态乙型肝炎病毒的再激活及防治[J].2009,(1).
[14]陈万青,郑荣寿,曾红梅,等.2011年中国恶性肿瘤发病和死亡分析[J].2015,(1).
[15]Feld, Jordan J.,Kramer, Barnett S.,Cryer, Donna R.,etc.Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update[J].2015,33(19).
[16]Jeong Won, Jang,Young Woon, Kim,Sung Won, Lee,etc.Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma.[J].2015,10.
[17]Lin TY,Huang Y,Zhai LZ,etc.Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy.[J].2011,18(12).
[18]Chayama,K.,Ohishi,W..Treatment of chronic hepatitis B with nucleos(t)ide analogues[J].2012,42(3).
[19]Chien-Yuan, Chen,Sheng-Yi, Huang,Aristine, Cheng,etc.High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia.[J].2015,10.
[20]Firpi RJ,Nelson DR.Management of viral hepatitis in hematologic malignancies.[J].2008,22(3).
[21]Xu,L.,Tu,Z.,Xu,G.,etc.Epirubicin directly promotes hepatitis B virus (HBV) replication in stable HBV-expressing cell lines: A novel mechanism of HBV reactivation following anticancer chemotherapy[J].2014,9(4).
[22]Cui, Gang,Liang, Xiaofeng,Yang, Weizhong,etc.Epidemiological serosurvey of Hepatitis B in China-Declining HBV prevalence due to Hepatitis B vaccination[J].2009,27(47).
[23]Wen-Chi, Chen,Jin-Shiung, Cheng,Po-Hung, Chiang,etc.A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy.[J].2015,10.
[24]D'Aniello, Carmine,Maruzzo, Marco,Basso, Umberto.Prevention of Hepatitis B Virus Reactivation With Lamivudine in a Patient With Advanced Renal Cell Carcinoma Treated With Everolimus[J].2016,23(3).
[25]Jeong Won Jang.Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy[J].2014,(24).
[26]陈建霖,管灵素,张晓红.血液系统恶性肿瘤患者乙型肝炎病毒感染的临床分析[J].2013,(1).
[27]Ann-Lii Cheng,Chao A. Hsiung,Ih-Jen Su,etc.Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma[J].2003,37(6).
[28]Cindy M, Weinbaum,Ian, Williams,Eric E, Mast,etc.Recommendations for identification and public health management of persons with chronic hepatitis B virus infection.[J].2008,57(RR-8).
[29]Min Kyoung, Kim,Jin Hee, Ahn,Sung-Bae, Kim,etc.Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience.[J].2007,22.
[30]Chen,F.W.,Pattullo,V.,Jones,B.E.,etc.Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease[J].2013,33(8).
[31]Yuan-Qing Zhang,Jin-Sheng Guo.Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma[J].2015,(13).
[32]Ha Ra, Gu,Dong-Yeop, Shin,Hong Seok, Choi,etc.HBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT.[J].2015,50(1).
[33].Hepatitis B virus reactivation during immunosuppressivetherapy: Appropriate risk stratification[J].2015,0(6).
[34]Vierling,J.M.,Hwang,J.P.,Loomba,R.,etc.Hepatitis B virus management to prevent reactivation after chemotherapy: A review[J].2012,20(11).
[35]Jessica P Hwang,Anna S-F Lok.Management of patients with hepatitis B who require immunosuppressive therapy.[J].2014,11(4).
[36]Lok Anna S.F.,Liang Raymond H.S.,Chiu Edmond K.W.,etc.Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy[J].1991.
[37].Hepatitis B reactivation in the setting of chemotherapy andimmunosuppression - prevention is better than cure[J].2015,0(7).
[38]孙德聪,陈丽,吴志勇,等.化疗相关乙肝病毒再激活的诊治现状[J].2014,(5).